Overview Financials News + Filings IR Vault Key Docs Charts Transactions Holdings Ownership Insiders
|
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| MedSurg | | | | 6,045.0 | 5,557.0 | 4,894.0 | 3,895.0 | 3,781.0 |
| Orthopaedics | | | | 4,991.0 | 4,713.0 | 4,422.0 | 4,223.0 | 4,153.0 |
| Neurotechnology & Spine | | | | 2,565.0 | 2,174.0 | 2,009.0 | 1,828.0 | 1,741.0 |
| Total revenues | 17,108.0 | 14,351.0 | 14,884.0 | 13,601.0 | 12,444.0 | 11,325.0 | 9,946.0 | 9,675.0 |
| Revenue growth [+] | 19.2% | -3.6% | 9.4% | 9.3% | 9.9% | 13.9% | 2.8% | 7.2% |
| MedSurg | | | | 8.8% | 13.5% | 25.6% | 3.0% | 10.7% |
| Orthopaedics | | | | 5.9% | 6.6% | 4.7% | 1.7% | 5.2% |
| Neurotechnology & Spine | | | | 18.0% | 8.2% | 9.9% | 5.0% | 5.0% |
| Cost of goods sold | 6,140.0 | 5,294.0 | 5,188.0 | 4,663.0 | 4,264.0 | 3,821.0 | 3,344.0 | 3,319.0 |
| Gross profit | 10,968.0 | 9,057.0 | 9,696.0 | 8,938.0 | 8,180.0 | 7,504.0 | 6,602.0 | 6,356.0 |
| Gross margin | 64.1% | 63.1% | 65.1% | 65.7% | 65.7% | 66.3% | 66.4% | 65.7% |
| Selling, general and administrative | 6,427.0 | 5,361.0 | 5,356.0 | 5,099.0 | 4,552.0 | 4,137.0 | 3,610.0 | 3,547.0 |
| Research and development | 1,235.0 | 984.0 | 971.0 | 862.0 | 787.0 | 715.0 | 625.0 | 614.0 |
| Other operating expenses | 103.0 | 17.0 | 192.0 | 23.0 | 173.0 | 158.0 | 296.0 | 761.0 |
| EBITDA [+] | 3,574.0 | 3,035.0 | 3,491.0 | 3,260.0 | 2,939.0 | 2,721.0 | 2,258.0 | 1,624.0 |
| EBITDA growth | 17.8% | -13.1% | 7.1% | 10.9% | 8.0% | 20.5% | 39.0% | 3.9% |
| EBITDA margin | 20.9% | 21.1% | 23.5% | 24.0% | 23.6% | 24.0% | 22.7% | 16.8% |
| Depreciation | 371.0 | 340.0 | 314.0 | 306.0 | 271.0 | 227.0 | 187.0 | 190.0 |
| EBITA | 3,203.0 | 2,695.0 | 3,177.0 | 2,954.0 | 2,668.0 | 2,494.0 | 2,071.0 | 1,434.0 |
| EBITA margin | 18.7% | 18.8% | 21.3% | 21.7% | 21.4% | 22.0% | 20.8% | 14.8% |
| Amortization of intangibles | 619.0 | 472.0 | 464.0 | 417.0 | 371.0 | 319.0 | 210.0 | 188.0 |
| EBIT [+] | 2,584.0 | 2,223.0 | 2,713.0 | 2,537.0 | 2,297.0 | 2,175.0 | 1,861.0 | 1,246.0 |
| EBIT growth | 16.2% | -18.1% | 6.9% | 10.4% | 5.6% | 16.9% | 49.4% | -0.8% |
| EBIT margin | 15.1% | 15.5% | 18.2% | 18.7% | 18.5% | 19.2% | 18.7% | 12.9% |
| Interest expense | | | | | | | | |
| Interest expense | 337.0 | 315.0 | 287.0 | 264.0 | 247.0 | 228.0 | 108.0 | 113.0 |
| Other income (expense), net | 34.0 | 46.0 | 136.0 | 83.0 | 13.0 | -26.0 | -18.0 | 27.0 |
| Pre-tax income | 2,281.0 | 1,954.0 | 2,562.0 | 2,356.0 | 2,063.0 | 1,921.0 | 1,735.0 | 1,160.0 |
| Income taxes | 287.0 | 355.0 | 479.0 | -1,197.0 | 1,043.0 | 274.0 | 296.0 | 645.0 |
| Tax rate | 12.6% | 18.2% | 18.7% | | 50.6% | 14.3% | 17.1% | 55.6% |
| Net income | 1,994.0 | 1,599.0 | 2,083.0 | 3,553.0 | 1,020.0 | 1,647.0 | 1,439.0 | 515.0 |
| Net margin | 11.7% | 11.1% | 14.0% | 26.1% | 8.2% | 14.5% | 14.5% | 5.3% |
| |
| Basic EPS [+] | $5.29 | $4.26 | $5.57 | $9.50 | $2.73 | $4.40 | $3.82 | $1.36 |
| Growth | 24.2% | -23.5% | -41.4% | 248.2% | -38.1% | 15.2% | 180.8% | -48.8% |
| Diluted EPS [+] | $5.22 | $4.20 | $5.48 | $9.34 | $2.68 | $4.35 | $3.78 | $1.35 |
| Growth | 24.1% | -23.3% | -41.3% | 248.2% | -38.3% | 15.2% | 180.8% | -48.9% |
| |
| Dividends per share [+] | $2.52 | $2.30 | $2.08 | $1.88 | $1.70 | $1.52 | $1.38 | $1.26 |
| Growth | 9.6% | 10.5% | 10.7% | 10.5% | 12.0% | 9.7% | 9.8% | 14.5% |
| |
| Shares outstanding (basic) [+] | 377.0 | 375.5 | 374.0 | 374.1 | 374.0 | 374.1 | 376.6 | 378.5 |
| Growth | 0.4% | 0.4% | 0.0% | 0.0% | 0.0% | -0.7% | -0.5% | 0.0% |
| Shares outstanding (diluted) [+] | 382.3 | 380.3 | 379.9 | 380.3 | 380.1 | 378.5 | 380.9 | 382.8 |
| Growth | 0.5% | 0.1% | -0.1% | 0.1% | 0.4% | -0.6% | -0.5% | 0.2% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|